Cargando…

Thinking about cognition: concepts, targets and therapeutics /

100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Adva...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam ; Washington, DC : IOS Press, ©2006.
Colección:Solvay Pharmaceuticals Conferences ; v. 5.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 a 4500
001 EBOOKCENTRAL_ocn124095086
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cnu---unuuu
008 070510s2006 ne a ob 101 0 eng d
010 |z  2006938638 
040 |a N$T  |b eng  |e pn  |c N$T  |d OCLCQ  |d IDEBK  |d OCLCQ  |d OCLCO  |d OCLCF  |d NLGGC  |d YDXCP  |d OCLCQ  |d ADU  |d E7B  |d SFB  |d EBLCP  |d IOSPR  |d DKDLA  |d MHW  |d OCLCQ  |d N9V  |d D6H  |d AZK  |d OCLCQ  |d AGLDB  |d OCLCO  |d COCUF  |d TOA  |d OCLCO  |d OCLCQ  |d OCLCO  |d MOR  |d PIFBR  |d ZCU  |d OCLCQ  |d MERUC  |d OCLCQ  |d U3W  |d OCLCO  |d STF  |d WRM  |d VNS  |d OCLCO  |d VTS  |d OCLCO  |d ICG  |d VT2  |d AU@  |d OCLCQ  |d OCLCO  |d WYU  |d OCLCO  |d S9I  |d OCLCO  |d DKC  |d OCLCO  |d OCLCQ  |d M8D  |d OCLCA  |d CEF  |d UKCRE  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCL  |d VLY  |d SDF  |d TUHNV 
016 7 |a 101316462  |2 DNLM 
019 |a 212941058  |a 243615875  |a 465672525  |a 475744259  |a 491261269  |a 614486372  |a 648166597  |a 744981633  |a 814477760  |a 955665607  |a 960883481  |a 961579243  |a 962618111  |a 966240328  |a 974149822  |a 974435414  |a 988508041  |a 992101844  |a 1018003753  |a 1029495536  |a 1037777101  |a 1038666462  |a 1041914203  |a 1055399811  |a 1064017946  |a 1065078671  |a 1081295498  |a 1086940857  |a 1096478524  |a 1153509276  |a 1162533735  |a 1200855461  |a 1228582123 
020 |a 9781429467711  |q (electronic bk.) 
020 |a 1429467711  |q (electronic bk.) 
020 |a 1280810556 
020 |a 9781280810558 
020 |a 143370157X  |q (electronic bk. ;  |q Adobe Reader) 
020 |a 9781433701573  |q (electronic bk. ;  |q Adobe Reader) 
020 |a 9781607502180 
020 |a 1607502186 
020 |z 1586037021  |q (hardcover) 
020 |z 9781586037024  |q (hardcover) 
029 1 |a AU@  |b 000043833327 
029 1 |a AU@  |b 000051417193 
029 1 |a AU@  |b 000062627407 
029 1 |a DEBBG  |b BV043101231 
029 1 |a DEBBG  |b BV044122935 
029 1 |a DEBSZ  |b 422216623 
029 1 |a GBVCP  |b 802281605 
029 1 |a NLGGC  |b 306367831 
029 1 |a NLGGC  |b 38222454X 
029 1 |a NLM  |b 101316462 
029 1 |a NZ1  |b 14237291 
035 |a (OCoLC)124095086  |z (OCoLC)212941058  |z (OCoLC)243615875  |z (OCoLC)465672525  |z (OCoLC)475744259  |z (OCoLC)491261269  |z (OCoLC)614486372  |z (OCoLC)648166597  |z (OCoLC)744981633  |z (OCoLC)814477760  |z (OCoLC)955665607  |z (OCoLC)960883481  |z (OCoLC)961579243  |z (OCoLC)962618111  |z (OCoLC)966240328  |z (OCoLC)974149822  |z (OCoLC)974435414  |z (OCoLC)988508041  |z (OCoLC)992101844  |z (OCoLC)1018003753  |z (OCoLC)1029495536  |z (OCoLC)1037777101  |z (OCoLC)1038666462  |z (OCoLC)1041914203  |z (OCoLC)1055399811  |z (OCoLC)1064017946  |z (OCoLC)1065078671  |z (OCoLC)1081295498  |z (OCoLC)1086940857  |z (OCoLC)1096478524  |z (OCoLC)1153509276  |z (OCoLC)1162533735  |z (OCoLC)1200855461  |z (OCoLC)1228582123 
050 4 |a BF311  |b .T45 2006eb 
060 4 |a 2007 L-331 
060 4 |a WM 204  |b T443 2006 
072 7 |a SCI  |x 090000  |2 bisacsh 
072 7 |a PSY  |x 008000  |2 bisacsh 
072 7 |a K  |2 bicssc 
082 0 4 |a 153  |2 22 
049 |a UAMI 
245 0 0 |a Thinking about cognition: concepts, targets and therapeutics /  |c C.G. Kruse [and others] (eds.). 
260 |a Amsterdam ;  |a Washington, DC :  |b IOS Press,  |c ©2006. 
300 |a 1 online resource (ix, 133 pages) :  |b illustrations (some color) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a data file 
490 1 |a Solvay Pharmaceuticals Conferences,  |x 1566-7685 ;  |v v. 5 
500 |a International conference proceedings. 
520 |a 100 Years after the discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world population is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological isorders such as schizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks s transforming our view of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and earning impairment. In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comprehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia vascular dementia, retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 100 Years after te discovery of Alzheimer's disease, neurological diseases and psychiatric disorders represent the largest and fastest growing unmet medical market with 2 billion affected people worldwide. Life expectancy of humans continues to increase, and the world poplation is aging. Advanced age may lead to deterioration of cognitive functions of the brain. There seems to be consensus that on the background of aging, several factors may render humans prone to dementia. Psychiatric and neurological disorders such as shizophrenia, bipolar disorder or Parkinson's disease may contribute to development of dementia. More people today are looking for help regarding their learning and memory capabilities. Although increasing knowledge on neuronal networks is transforming ourview of the human brain and its function and we understand psychiatric and neurological diseases better today than ever before, novel therapies are needed to respond to the growing demand of patients for assistance with memory loss and learning impairment In fact, it is expected that novel therapies aiming at the processing of amyloid, or at activation of glutamatergic or nicotinergic systems will demonstrate adequate efficacy in improving learning and memory disturbances. This publication stands as a comrehensive overview of the cellular and molecular mechanisms underlying the development of cognitive impairment. It integrates discoveries concerning dementia, such as mild cognitive impairment and Alzheimer's disease associated dementia, vascular dementia retardation syndromes, and psychiatric and neurological disorders related cognitive impairments. This book will be useful to physicians, biologists, and those pursuing an interest or concerned with memory impairment. 
588 0 |a Print version record. 
504 |a Includes bibliographical references and index. 
505 0 |a Title page; Preface; List of Contributors; Contents; Conference Preface; Keynote Lecture -- The Meaning of Cognition in our Society and Health Care Systems; Age-Associated Memory Impairment; Cognition in Alzheimer's Disease and Related Disorders; Cognitive Deficits as a Core Feature of Schizophrenia; Cognition in Depression and Mania; Linking Pre-Clinical and Clinical Approaches to Therapy for Cognitive Dysfunction in Neuropsychiatric and Neurodegenerative Disorders; Pre-Clinical Models of Cognition: The Role of the Cannabis Subtype 1 Receptor. 
546 |a English. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Cognition. 
650 0 |a Cognition  |x Age factors. 
650 0 |a Cognition  |x Effect of drugs on. 
650 1 2 |a Cognition Disorders  |x physiopathology 
650 2 2 |a Cognition Disorders  |x drug therapy 
650 2 |a Cognition 
650 6 |a Cognition. 
650 6 |a Cognition  |x Facteurs liés à l'âge. 
650 6 |a Cognition  |x Effets des médicaments sur. 
650 7 |a cognition.  |2 aat 
650 7 |a SCIENCE  |x Cognitive Science.  |2 bisacsh 
650 7 |a PSYCHOLOGY  |x Cognitive Psychology.  |2 bisacsh 
650 7 |a Cognition  |2 fast 
650 7 |a Cognition  |x Age factors  |2 fast 
650 7 |a Cognition  |x Effect of drugs on  |2 fast 
655 2 |a Congress 
655 7 |a proceedings (reports)  |2 aat 
655 7 |a Conference papers and proceedings  |2 fast 
655 7 |a Conference papers and proceedings.  |2 lcgft 
655 7 |a Actes de congrès.  |2 rvmgf 
758 |i has work:  |a Thinking about Cognition (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCXDFqtrKhgTppd9xhdbFfC  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |t Thinking about cognition.  |d Amsterdam ; Washington, DC : IOS Press, ©2006  |z 9781586037024  |w (DLC) 2006938638  |w (OCoLC)137305488 
830 0 |a Solvay Pharmaceuticals Conferences ;  |v v. 5.  |x 1566-7685 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=287005  |z Texto completo 
938 |a EBL - Ebook Library  |b EBLB  |n EBL287005 
938 |a ebrary  |b EBRY  |n ebr10167406 
938 |a EBSCOhost  |b EBSC  |n 187951 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n 81055 
938 |a YBP Library Services  |b YANK  |n 2557734 
938 |a YBP Library Services  |b YANK  |n 2625010 
938 |a YBP Library Services  |b YANK  |n 3207234 
994 |a 92  |b IZTAP